Drug Profile

Research programme: estrogen receptor antagonists - Olema Pharmaceuticals

Alternative Names: OP 1074

Latest Information Update: 28 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Olema Pharmaceuticals
Class Antineoplastics
Mechanism of Action Estrogen receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Breast cancer

Most Recent Events

28 May 2022 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO)
17 Mar 2018 Pharmacodynamics data from a preclinical study in Breast cancer presented at the The 100^th Annual Meeting of the Endocrine Society (AMES-2018)
01 Mar 2018 Preclinical trials in Breast cancer in USA (PO), before March 2018

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com